News

Research findings from the multicentre clinical study were presented at the European Society of Ophthalmology (SOE) meeting in Lisbon, Portugal

Special programming for young ophthalmologists will be hosted in the YO lounge

This year’s multi-specialty programme features the SOE Leadership Development Programme (EuLDP), the International Society of Ocular Trauma (ISOT), European University Professors of Ophthalmology (EUPO) and more

VG801 is a dual AAV gene therapy that leverages mRNA trans-splicing via the vgRNA REVeRT and vgAAV platforms to deliver the full-length ABCA4 gene for Stargardt disease and related retinal disorders.

Researchers share that perfluorohexyloctane eye drops offer rapid relief for dry eye disease, enhancing patient comfort before cataract surgery.

Retina specialist Jay Chhablani, MD, discusses 3D choroidal vessel segmentation, uncovering critical insights into macular degeneration, diabetic retinopathy, and potential systemic disease connections using advanced OCT technology.

The preservative-free, contact lens–friendly drops have been formulated to provide hydration and comfort for dry eyes in a multidose bottle.

Centennial Optical distributes ophthalmic frames, eyeglass lenses, sunglasses, lab supplies, and optical accessories.

Boyer discusses a potential treatment for diabetic retinopathy and macular degeneration using suprachoroidal injections, offering reduced risks and improved outcomes.

Gore recently launched its silicone-free GORE IMPROJECT Plunger for 0.5-mL pre-filled syringes for the delivery of ophthalmic drugs.

Brazilian ANVISA has granted marketing authorisation for FYB201 (Ranivisio), a biosimilar to Lucentis.

VG801 is a dual AAV gene therapy that leverages mRNA trans-splicing via the vgRNA REVeRT and vgAAV platforms to deliver the full-length ABCA4 gene for Stargardt disease and related retinal disorders.

OCU400 is Ocugen’s novel modifier gene therapy for retinitis pigmentosa (RP).

The 0.1 mg/ml atropine eye drop for paediatric myopia is licensed from Sydnexis, Inc.

Areas covered by the agreement would cover key Asian marketplaces, including Japan and China.

IVMED-85 is a preservative-free, non-atropine daily drop that slows myopia progression by strengthening scleral and corneal collagen crosslinks via LOX activation.

International retina specialists converge to explore groundbreaking treatments, drug delivery systems, and surgical innovations at the Retina World Congress 2025.

Weighing the benefits and trade-offs of preserved versus preservative-free glaucoma treatments is key to optimizing long-term patient care.

Retinal vascular change or degeneration already has been associated with Alzheimer and Parkinson disease, and the findings suggest that neurologic diseases impact ocular health.

At the 2025 ASCRS meeting, Dr. Sarkisian presented 3-year data on the iDose TR from the FDA clinical trial.

Long-term benefits and vision preservation using an extended macular vision IOL

Insights from a genome-wide association study identify novel genetic loci

Prevent Blindness offers resources for Cataract Month, empowering patients and caregivers with knowledge on cataracts and surgery options.

The FDA has set a Prescription Drug User Fee Act (PDUFA) date of January 28, 2026.

A recent US Court of International Trade decision was made on May 28 to permanently prohibit all tariffs imposed by President Donald Trump under the International Emergency Economic Powers Act.

Telomir-1 shows promising results in restoring vision and retinal structure in age-related macular degeneration, marking a significant advancement in treatment.